证券代码：688607 证券简称：康众医疗 江苏康众数字医疗科技股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |------------|-----------------------------------------------------------------------------------------------------|-------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系 | □新闻发布会 □路演活动 | | | 活动类别 | □现场参观 ■一对一沟通 | | | | □其他 | | | | 2022 年 6 月 10 日： | | | | 华西证券自营 银华基金 | | | | 2022 年 6 月 16 日： | | | | 工银瑞信 | | | | 2022 年 6 月 17 日： | | | | 建信养老 | | | | 2022 年 6 月 20 日： 高毅资产 中融基金 鹏华基金 2022 年 6 月 21 日： 汇添富基金 | | | 参与单位 | 2022 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[13]. - The company's operating revenue for the first half of 2022 was ¥100,695,960.53, a decrease of 43.20% compared to the same period last year[20]. - The net profit attributable to shareholders was -¥2,772,198.14, a significant decline from ¥46,517,819.95 in the previous year[22]. - The net cash flow from operating activities was -¥19,422,490.73, indicating a decrease due to reduced sales revenue[22]. - Basic earnings per share were -¥0.03, down from ¥0.55 in the same period last year[21]. - The total comprehensive income for the first half of 2022 was CNY -2.09 million, a significant decrease from CNY 46.17 million in the same period of 2021[175]. - The company reported a net loss of 110,000 RMB for the investment segment, with total revenue of 4,945,490 RMB, reflecting a growth rate of 5.61%[150]. - The company reported a financial expense of CNY -7.32 million in the first half of 2022, compared to CNY -1.30 million in the same period of 2021, indicating a significant increase in financial costs[174]. Research and Development - Research and development expenses increased by 30%, totaling RMB 15 million, to support innovation in medical imaging technology[13]. - Research and development expenses accounted for 22.26% of operating revenue, an increase of 14.92 percentage points year-on-year[21]. - The company reported a significant increase in R&D expenditures, totaling approximately ¥22.41 million in the current period compared to ¥13.01 million in the same period last year, with R&D expenses accounting for 22.26% of operating revenue[51]. - The number of R&D personnel increased to 83, representing 33.60% of the total workforce, up from 31.46% in the previous year[58]. - The R&D team is composed of highly qualified professionals, with 5 holding doctoral degrees and 33 holding master's degrees, enhancing the company's innovation capabilities[58]. - The company is focusing on the development of customized non-conventional flat panel detectors and advanced technologies such as CMOS sensors and IGZO applications[61]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[13]. - The company has established partnerships with three new distributors to enhance its sales network in the domestic market[13]. - The company is exploring market expansion opportunities, particularly in the investment management sector, to enhance revenue streams[150]. - The company plans to establish a wholly-owned subsidiary in Singapore with an investment of up to $15 million to enhance long-term strategic planning[93]. - The company is focused on optimizing its cost structure through various measures, including enhancing supply chain management and increasing automation levels[75]. Risks and Challenges - The management highlighted potential risks related to regulatory changes in the medical device industry, which could impact future operations[4]. - The company faces risks related to talent retention and potential core technology leaks, which could impact product development and operational performance[77][78]. - The company is expanding its overseas operations, establishing sales service centers in countries like the USA, India, and Japan, which may be affected by changes in market conditions and trade policies[79]. Product Development and Innovation - New product launches include an advanced digital X-ray imaging system, which is expected to enhance market competitiveness[13]. - The company is developing a new type of DR imaging system with a focus on optimizing resolution and achieving precise imaging[55]. - The company has launched new products in the fields of new energy battery testing and electronic testing, achieving full coverage of major application areas by the end of the reporting period[44]. - The company aims to enhance the portability of flat panel detectors through hardware and firmware restructuring[55]. - The company is focusing on market expansion through the introduction of innovative imaging technologies[55]. Financial Health and Assets - The company's total assets decreased by 5.00% to ¥894,043,385.88 compared to the end of the previous year[20]. - The net assets attributable to shareholders decreased by 3.17% to ¥843,255,568.31[20]. - Cash and cash equivalents decreased by 53.02% to ¥167,033,405.34, primarily due to reduced bank deposits[91]. - The total liabilities decreased to ¥50,795,804.49 from ¥70,164,253.35, indicating a reduction of about 27.5%[164]. - The company's total equity attributable to shareholders decreased to ¥843,255,568.31 from ¥870,901,046.65, reflecting a decline of approximately 3.2%[164]. Shareholder Commitments and Governance - The actual controller and shareholders of the company have committed to not transferring or entrusting the management of their shares for 36 months from the listing date[110]. - The company has established strict compliance with relevant laws and regulations regarding share transfers and commitments[111]. - The company emphasizes the importance of maintaining shareholder confidence through these commitments[110]. - The company will ensure clear control arrangements and stable operations during any share reduction process[113]. - The company will implement specific measures to stabilize its stock price if the closing price is below the audited net asset value per share for 20 consecutive trading days[113].

Financial Performance - The company's operating revenue for Q1 2022 was ¥38,090,182.58, representing a decrease of 57.09% compared to the same period last year[5]. - Total operating revenue for Q1 2022 was ¥38,090,182.58, a decrease of 57.0% compared to ¥88,763,204.08 in Q1 2021[21]. - Net profit for Q1 2022 was a loss of ¥7,232,998.53, compared to a profit of ¥22,426,173.56 in Q1 2021, representing a significant decline[22]. - The company reported a total comprehensive loss of ¥7,035,964.29 for Q1 2022, compared to a comprehensive income of ¥22,061,293.60 in Q1 2021[23]. - Basic and diluted earnings per share for Q1 2022 were both -¥0.08, compared to ¥0.28 in Q1 2021[23]. - Operating profit for Q1 2022 was ¥419,246.32, significantly down from ¥21,933,841.49 in Q1 2021[31]. - The net profit for Q1 2022 was a loss of ¥147,360.51, compared to a profit of ¥18,478,746.72 in Q1 2021[31]. Cash Flow and Investments - The net cash flow from operating activities was -¥18,775,283.32, primarily due to reduced revenue and increased R&D investments[10]. - The net cash flow from operating activities was -18,775,283.32 RMB, a significant decline compared to -4,232,062.58 RMB in the previous year, indicating a worsening operational cash flow situation[25]. - Cash received from sales of goods and services in Q1 2022 was ¥56,661,168.42, down 38.8% from ¥92,637,961.48 in Q1 2021[24]. - Total cash inflow from investment activities reached 786,814,946.45 RMB, a substantial increase from 256,050,152.64 RMB year-over-year, driven by other investment-related cash receipts of 783,396,660.00 RMB[25]. - The cash outflow for investment activities was 905,748,368.54 RMB, significantly higher than 307,815,110.11 RMB in the previous year, reflecting increased investment expenditures[25]. - The company reported a significant increase in investment activity cash inflow to ¥786,814,946.45 in Q1 2022, compared to ¥256,050,152.64 in Q1 2021[34]. - Total cash outflow from investment activities was ¥903,750,875.08 in Q1 2022, compared to ¥307,399,200.00 in Q1 2021[34]. Research and Development - Research and development expenses totaled ¥10,773,753.92, accounting for 28.28% of operating revenue, an increase of 21.22 percentage points year-on-year[6]. - Research and development expenses for Q1 2022 were ¥10,773,753.92, an increase of 72.5% from ¥6,262,597.54 in Q1 2021[21]. - Research and development expenses increased to ¥10,150,811.74 in Q1 2022, up 88.5% from ¥5,386,318.21 in Q1 2021[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥924,585,651.53, a decrease of 1.75% from the end of the previous year[6]. - The company's total assets amounted to RMB 924,585,651.53, a decrease from RMB 941,065,240.00 as of December 31, 2021, reflecting a decline of approximately 1.75%[16]. - The company's cash and cash equivalents were RMB 216,869,303.99, down from RMB 355,514,192.05, indicating a decrease of about 39.0%[16]. - Total liabilities as of Q1 2022 amounted to ¥59,176,234.81, a decrease from ¥70,164,253.35 in the previous year[19]. - The total liabilities decreased to 55,901,853.71 RMB from 65,182,854.84 RMB, showing a reduction in the company's debt levels[29]. - The company's total equity increased slightly to 851,473,124.06 RMB from 850,076,090.21 RMB, indicating stable shareholder value[29]. Shareholder Information - The company had a total of 6,252 common shareholders at the end of the reporting period[12]. - The top shareholder, LIU JIANQIANG, held 12,810,000 shares, representing 14.54% of the total shares[12]. Other Information - The company received government subsidies amounting to ¥229,511.33 during the reporting period[7]. - The company reported a non-recurring gain of ¥3,287,259.65 after tax, primarily from investment income[8]. - The company has not disclosed any new product or technology developments in this quarter[15]. - There are no significant mergers or acquisitions reported during this period[15].

Financial Performance - The company achieved operating revenue of CNY 341,984,505.45, representing a year-on-year growth of 0.81%[24]. - The net profit attributable to shareholders was CNY 85,089,972.00, an increase of 13.24% compared to the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 73,552,636.81, up by 9.70% year-on-year[24]. - Total assets at the end of the reporting period reached CNY 941,065,240.00, reflecting a growth of 118.07% from the beginning of the year[24]. - The net assets attributable to shareholders increased to CNY 870,901,046.65, a rise of 136.14% compared to the previous year[24]. - The basic earnings per share were CNY 0.99, down 13.16% from the previous year[23]. - The overall gross margin improved from 43.40% in 2020 to 46.10% in 2021, reflecting enhanced profitability through cost control measures[40]. - The company reported a significant increase in trading financial assets, with a total balance of ¥345,666,811.87 at the end of the period, reflecting a change of ¥185,228,882.66[32]. - The company reported a total revenue of 37,777,959.00 RMB, with a net profit of 11,544,906.08 RMB for the year 2021[83]. Dividend Policy - The company plans to distribute a cash dividend of RMB 2.90 per 10 shares, totaling approximately RMB 25.56 million, which represents 30.04% of the net profit attributable to shareholders for the year 2021[5]. - The company has not proposed any capital reserve transfer to increase share capital or stock dividends for the year 2021, focusing on cash dividends instead[5]. - The company has a cash dividend policy that mandates at least 10% of the distributable profit to be allocated for cash dividends if the net profit is positive[193]. - In mature stages without significant capital expenditure, the cash dividend proportion should be at least 80% of the distributable profit[193]. - The dividend distribution plan has been approved by the company's board and supervisory board, pending approval from the 2021 annual general meeting[198]. - The company will not conduct capital reserve transfers to increase share capital or issue bonus shares for the year[198]. - The company has confirmed that the dividend distribution standards and proportions are clear and comply with the company's articles of association[199]. - Independent directors have fulfilled their responsibilities and provided clear opinions on the dividend distribution plan[199]. Governance and Compliance - The board of directors and management have confirmed the accuracy and completeness of the financial report, ensuring accountability for the information presented[4]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties, indicating a stable financial governance structure[8]. - There are no violations of decision-making procedures regarding external guarantees, reflecting adherence to regulatory compliance[9]. - The company adheres to strict governance practices, ensuring that all shareholder rights, especially for minority shareholders, are protected[149]. - The company has developed a comprehensive governance structure in line with the Company Law and relevant regulations, enhancing decision-making processes[150]. - The company maintains independence in operations, with no interference from actual controllers in decision-making activities[154]. - The company has complied with information disclosure obligations, maintaining good interaction with investors[156]. - The company has established a complete decision-making process for the dividend distribution[199]. Research and Development - The R&D expenditure accounted for 9.46% of operating revenue, an increase of 1.78 percentage points year-on-year[23]. - The company reported a 24.17% increase in R&D expenses, totaling ¥32,366,646.41, which represents 9.46% of total revenue[80][81]. - The number of R&D personnel increased to 79, representing 33.05% of the total workforce, up from 28.27% in the previous year[85]. - The company is focusing on developing unconventional flat panel detector manufacturing technologies and integrating AI and dual-energy imaging technologies to improve product performance and reduce production costs[139]. - The company is investing in projects such as the development of a new type of pet DR imaging system, with a total expected investment of ¥4,500,000[82]. - The company is also working on a dual-energy flat panel detector, with an expected investment of ¥2,000,000, aimed at enhancing imaging capabilities[82]. - The company has made significant advancements in digital X-ray flat panel detector technology, ensuring high resolution and dynamic range at low doses[86]. - The company is actively developing new products, including a new integrated system solution for imaging systems, aiming for digitalization and intelligence[78]. Market Expansion and Strategy - The company aims to enhance domestic market expansion while addressing challenges in overseas business development due to the pandemic[34]. - The company is focusing on accelerating the development of new products and technologies to support stable business growth[34]. - The company plans to optimize its organizational structure and increase resource allocation to drive long-term stable development[34]. - The company has established a global sales and service network covering over 30 countries, enhancing its international market presence and collaboration with leading enterprises[92]. - The company is actively pursuing market expansion in Southeast Asia, South America, Europe, and the Middle East, leveraging new technologies and products for strategic partnerships[144]. - The company has plans to expand its market presence by leveraging advancements in technology and increasing its R&D capabilities[77][78]. - The company is committed to developing integrated system solutions, transitioning from single product delivery to comprehensive service offerings[68]. - The company is investing $100 million in research and development for innovative technologies aimed at enhancing product efficiency[170]. Operational Efficiency - The net cash flow from operating activities was CNY 31,530,199.18, a decrease of 55.71% compared to the previous year due to increased costs of materials, labor, and services[25]. - The company achieved high production efficiency and cost control through advanced technologies, such as cesium iodide coating techniques, which have improved production yield and reduced costs[91]. - Direct material costs for digital X-ray detectors decreased by 5.71% compared to the previous year, reflecting improved supplier negotiation capabilities and production efficiency[114]. - The company has established a strategy focused on technology innovation, product upgrades, and global business collaboration to drive stable and rapid growth[141]. - The company is committed to continuous improvement in production processes and automation to optimize cost structures and enhance profitability[146]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the management discussion section of the report[4]. - The company faces risks related to management capacity as it scales operations, which may impact its competitive edge if not addressed effectively[94]. - The company faces risks from market demand fluctuations and intensified competition in the digital X-ray flat panel detector industry[99]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting the importance of risk awareness[7].

Financial Performance - The company's revenue for Q3 2021 was ¥73,660,695.36, a decrease of 30.55% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2021 was ¥17,119,345.75, down 34.55% year-on-year[5] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥12,789,204.13, a decline of 43.51% compared to the previous year[6] - Basic and diluted earnings per share for Q3 2021 were both ¥0.19, representing a decrease of 52.70% year-on-year[6] - Total revenue for the first three quarters of 2021 reached ¥250,934,141.22, an increase of 9.06% compared to ¥228,879,089.29 in the same period of 2020[21] - Operating profit for the third quarter was ¥77,386,519.29, up from ¥55,940,185.68 in the previous year, reflecting a growth of 38.34%[22] - Net profit attributable to shareholders for the first three quarters was ¥63,637,165.70, compared to ¥45,946,795.57 in the same period last year, marking an increase of 38.54%[22] - Total comprehensive income for the third quarter of 2021 reached CNY 63,334,607.84, an increase from CNY 45,944,124.54 in the same period last year, representing a growth of approximately 38%[23] - Basic and diluted earnings per share for the third quarter were CNY 0.74, up from CNY 0.70 in the previous year, indicating a 5.71% increase[23] Assets and Liabilities - The company's total assets increased to ¥939,514,196.41, reflecting a growth of 117.71% compared to the end of the previous year[6] - Total assets as of the end of the third quarter amounted to ¥939,514,196.41, significantly higher than ¥431,546,055.04 at the end of the previous year[21] - Current liabilities totaled ¥81,483,752.10, an increase from ¥57,544,653.66 in the same period last year, indicating a rise of 41.49%[20] - The total liabilities of the company reached ¥89,957,930.64, compared to ¥62,703,014.06 in the same period last year, indicating an increase of 43.38%[20] - Total liabilities amounted to 62,703,014.06, a decrease of 5,261,300.78 from the previous period[29] - The company reported a non-current liability total of 5,158,360.40, down from 7,393,770.06, indicating a reduction of 2,235,409.66[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 4,700[14] - The largest shareholder, Changcheng Co., Ltd., holds 13,089,380 shares, representing 14.8% of total shares[14] - Liu Jianqiang, another major shareholder, owns 12,810,000 shares, accounting for 14.5%[14] - The company reported a total of 1,685,163 shares held by Jiangsu Qianrong Capital Management Co., Ltd., representing 1.91% of total shares[15] - The company has a significant number of shareholders with unlimited sale conditions, including major investment funds[15] - The company is under the control of Liu Jianqiang and Gao Peng, who hold 46.10% and 41.64% of the shares in a related entity, respectively[15] - The company has not disclosed any other significant relationships or agreements among shareholders[15] Cash Flow and Investments - Cash flow from operating activities for the year-to-date period decreased by 65.06% to ¥16,308,165.89[12] - Cash inflows from operating activities totaled CNY 301,156,278.34, compared to CNY 261,374,753.26 in the prior year, reflecting a year-over-year increase of about 15.2%[25] - Net cash flow from operating activities was CNY 16,308,165.89, a decrease from CNY 46,678,774.18 in the same period last year, showing a decline of approximately 65%[25] - Cash inflows from investment activities were CNY 954,857,099.78, significantly higher than CNY 511,959,568.62 in the previous year, indicating an increase of approximately 86.5%[26] - Net cash flow from financing activities was CNY 445,262,473.91, a turnaround from a net outflow of CNY 34,534,283.95 in the same period last year[26] - The company received CNY 447,342,486.13 from investment, marking a substantial increase compared to the previous year[26] - The company reported a significant increase in cash received from tax refunds, amounting to CNY 13,451,932.29, compared to CNY 4,765,570.32 in the previous year, representing an increase of approximately 182%[25] Research and Development - Research and development expenses for Q3 2021 amounted to ¥8,191,092.36, an increase of 28.86% year-on-year, accounting for 11.12% of revenue[6] - Research and development expenses for the first three quarters were ¥21,199,544.39, up from ¥17,320,823.11 in the same period last year, reflecting a growth of 22.06%[21] Equity - The company reported a significant increase in total equity attributable to shareholders, which rose by 130.35% year-on-year[12] - The equity attributable to shareholders increased to ¥849,545,856.51 from ¥368,803,960.89, representing a growth of 130.00%[20] - Total equity attributable to shareholders reached 368,803,960.89, remaining unchanged from the previous period[29]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[14]. - The company's operating revenue for the first half of 2021 was CNY 177,273,445.86, representing a 44.35% increase compared to the same period last year[21]. - The net profit attributable to shareholders for the same period was CNY 46,517,819.95, a significant increase of 135.05% year-on-year[21]. - The net profit after deducting non-recurring gains and losses was CNY 40,571,952.14, up 127.53% from the previous year[21]. - The total revenue for the first half of 2021 was RMB 44,576.75 million, with a net profit of RMB 13,160.96 million, reflecting a significant performance[161]. - The net profit for the first half of 2021 reached CNY 42,652,125.51, representing a growth of 72.9% from CNY 24,679,876.11 in the first half of 2020[196]. - The total comprehensive income for the first half of 2021 was CNY 46,174,911.03, compared to CNY 20,169,077.18 in the first half of 2020, indicating a significant increase[193]. Market Expansion and Product Development - User data indicates a growth in active users to 1.5 million, a 15% increase compared to the previous half-year[14]. - The company plans to launch two new digital medical products by the end of 2021, aiming to capture a larger market share[14]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2023[14]. - The company is expanding its product layout in high-end application fields such as mammography and dynamic imaging, driven by technological advancements[45]. - The company has developed a portable intelligent bone age measurement device that has received medical device registration and is now in mass production, contributing to sales revenue[55]. - The company is actively developing unconventional flat panel detector manufacturing technologies and artificial intelligence applications to enhance product performance and reduce costs[47]. Research and Development - Research and development expenses increased by 30% to RMB 15 million, reflecting the company's commitment to innovation[14]. - The company achieved a total R&D investment of ¥13,008,452.03, representing an 18.64% increase compared to ¥10,964,376.64 in the previous period[77]. - The company filed 8 new invention patent applications and 6 new utility model patent applications during the reporting period, bringing the total patent applications to 74[74]. - The company has integrated AI technology with DR technology to enhance imaging analysis and improve diagnostic efficiency[72]. - The company has developed advanced technologies in digital X-ray flat panel detectors, including high-resolution and high dynamic range capabilities, enhancing its competitive edge[84]. Financial Position and Cash Flow - The company has maintained a strong cash position with RMB 50 million in cash reserves, ensuring liquidity for upcoming projects[14]. - Cash and cash equivalents increased by 159.19% to ¥247,525,733.26, primarily due to funds raised from the company's IPO[113]. - The net cash flow from operating activities decreased by 68.70% to CNY 5,869,713.67, primarily due to increased sales and corresponding costs[21]. - The net cash flow from investing activities was -¥300,043,801.12, primarily due to an increase in purchased financial products[110]. - The net cash flow from financing activities was ¥447,179,672.77, largely attributed to funds raised from the company's listing on the Shanghai Stock Exchange[110]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[14]. - The company faces risks related to talent retention and competition in the digital X-ray flat panel detector market, which could impact future performance[100][104]. - The company is expanding its overseas operations, establishing sales service centers in the U.S., India, and Japan, which exposes it to foreign market risks[101]. Corporate Governance and Compliance - The company held its annual general meeting on May 20, 2021, where all proposed resolutions were approved without any rejections[125]. - The company did not propose any profit distribution or capital reserve fund increase for the first half of 2021, with no dividends or bonus shares issued[128]. - The company reported no environmental violations or penalties during the reporting period, adhering strictly to national environmental laws and regulations[131]. - The company has committed to fulfilling promises made, with measures in place for any failures to do so, including timely disclosure and corrective actions[148]. Shareholder Information - The total number of shares increased from 66,096,770 to 88,129,027 shares after the public offering of 22,032,257 shares on February 1, 2021[165]. - The largest shareholder, Changcheng Co., Ltd., held 13,089,380 shares, all of which are subject to IPO lock-up until February 1, 2022[167]. - The company’s foreign shareholding remained significant at 31.78% post-issuance[164]. - The total number of ordinary shareholders at the end of the reporting period was 7,343[169].

Financial Performance - The company's operating revenue for 2020 was CNY 339,220,790.01, representing a growth of 44.63% compared to 2019[22]. - The net profit attributable to shareholders for 2020 was CNY 75,144,418.07, an increase of 55.96% year-over-year, driven by stable growth in sales and operating revenue[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 67,048,899.17, reflecting a 90.92% increase, primarily due to steady growth in sales scale and operating performance[24]. - The net cash flow from operating activities for 2020 was CNY 71,184,739.71, a significant increase of 229.78%, attributed to expanded sales and procurement scale[24]. - The company's total assets at the end of 2020 were CNY 431,546,055.04, a 12.66% increase from the previous year[22]. - The net assets attributable to shareholders at the end of 2020 were CNY 368,803,960.89, marking a 25.64% increase year-over-year[22]. - The basic earnings per share for 2020 were CNY 1.14, up 56.16% from CNY 0.73 in 2019[23]. - The company's operating costs increased to CNY 191,991,784.28, reflecting a growth of 46.50% year-on-year[113]. - Net profit reached CNY 75,114,846.17, marking a 55.90% increase from the previous year[101]. Dividend Policy - The company plans to distribute a cash dividend of RMB 3.40 per 10 shares, totaling RMB 29,963,869.18, which represents 39.88% of the net profit attributable to shareholders for 2020[5]. - The company will not issue bonus shares or convert capital reserves into share capital for the fiscal year 2020[162]. - The profit distribution plan requires approval from the shareholders' meeting after being passed by the board of directors and the supervisory board[162]. - The company must disclose the reasons for not proposing a cash dividend if it has positive distributable profits[164]. - The board of directors must consider the timing, conditions, and minimum ratio for cash dividends when formulating the distribution plan[158]. - The company is in a growth phase and has significant capital expenditure plans, thus the minimum cash dividend ratio should be at least 20%[157]. Research and Development - The company has developed core technologies in digital X-ray flat panel detectors, with a focus on independent innovation and R&D capabilities[34]. - The research and development expenditure as a percentage of operating revenue was 7.68%, a decrease of 0.55 percentage points compared to the previous year[23]. - The company achieved a total R&D investment of ¥26,065,609.83, representing a 34.97% increase compared to the previous year[74]. - The R&D investment accounted for 7.68% of the total operating revenue, a decrease of 0.55% from the previous year[74]. - The R&D team consists of 54 members, accounting for 28.27% of total employees, with 68.52% holding master's degrees or higher, ensuring a strong talent pool[94]. - The company has obtained a total of 22 authorized invention patents and 5 utility model patents by the end of 2020, with 3 new invention patents and 4 new utility model patents granted during the year[72]. Market Position and Strategy - The company has established a strong sales team, with products sold in over 30 countries and regions, indicating a robust international market presence[36]. - The company is involved in the drafting of industry standards for medical digital X-ray detectors, showcasing its leadership in the field[36]. - The company is actively researching new technologies such as AI imaging and dual-energy imaging, positioning itself for future advancements in the industry[35]. - The company plans to expand its product range in the medical/pet and industrial/security sectors, focusing on high-performance, lightweight wireless flat panel detectors[146]. - The company aims to increase its market presence both domestically and internationally, with established sales service centers in the US and India[148]. Operational Efficiency - The company has implemented effective cost control measures, resulting in improved production efficiency and reduced costs[96]. - The company maintains a stable operating model focused on the R&D, manufacturing, and sales of digital X-ray flat panel detectors, with no significant changes expected in the near future[46]. - The company focuses on technology research and development, continuously achieving product iteration through technological innovation and expanding product categories[49]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The ongoing COVID-19 pandemic has created uncertainties for future operations, despite strong performance in 2020[108]. - The company faces risks related to talent retention, particularly in high-education R&D positions, which could impact product development[104]. Compliance and Governance - The company has received a standard unqualified audit report from the accounting firm[5]. - The company has no special arrangements for corporate governance[9]. - The company is committed to complying with relevant laws and regulations regarding share transfers and lock-up agreements[169]. - The company emphasizes the importance of legal compliance and accountability for any violations of share transfer commitments[173].

Financial Performance - Operating revenue for the first quarter reached CNY 88,763,204.08, a 112.14% increase year-on-year[5] - Net profit attributable to shareholders surged by 836.00% to CNY 22,444,014.27 compared to the same period last year[5] - Basic earnings per share rose to CNY 0.28, reflecting a 600.00% increase year-on-year[7] - Total revenue for Q1 2021 reached ¥88,763,204.08, a significant increase of 112.5% compared to ¥41,841,807.86 in Q1 2020[28] - Net profit for Q1 2021 was ¥22,426,173.56, compared to ¥2,389,907.90 in Q1 2020, representing a substantial increase of 836.5%[30] - The company's operating revenue for Q1 2021 was ¥75,324,101.72, a 83.5% increase from ¥41,024,494.74 in Q1 2020[32] - The net profit for Q1 2021 reached ¥18,478,746.72, compared to ¥4,970,697.86 in Q1 2020, representing a 271.5% increase[33] Assets and Liabilities - Total assets increased by 110.25% to CNY 907,311,029.24 compared to the end of the previous year[5] - The company's total assets reached 907,311,029.24 RMB, compared to 431,546,055.04 RMB at the end of 2020[21] - Total current assets as of March 31, 2021, amounted to 868,164,467.12 RMB, a substantial increase from 396,478,661.72 RMB at the end of 2020[19] - The total liabilities as of March 31, 2021, were 69,064,208.52 RMB, up from 62,703,014.06 RMB at the end of 2020[21] - Total liabilities for Q1 2021 were ¥62,905,149.16, an increase from ¥58,861,354.62 in Q1 2020, reflecting a growth of 3.5%[25] - Current liabilities rose to 60,570,544.78 RMB, an increase of 3,025,891.12 RMB compared to the previous year[43] Shareholder Information - Net assets attributable to shareholders increased by 127.28% to CNY 838,225,581.34 compared to the end of the previous year[5] - The total number of shareholders reached 8,755 by the end of the reporting period[11] - The top shareholder, Changcheng Co., Ltd., holds 14.85% of the shares, totaling 13,089,380 shares[12] - Jianqiang Liu, a natural person, holds 14.54% of the shares, totaling 12,810,000 shares[12] - Shareholders' equity totaled ¥819,105,865.64 in Q1 2021, compared to ¥353,284,632.79 in Q1 2020, representing an increase of 132.5%[25] Cash Flow - The company reported a net cash flow from operating activities of CNY -4,232,062.58, compared to CNY 6,372,316.49 in the same period last year[5] - The net cash flow from operating activities for Q1 2021 was -4,232,062.58 RMB, a significant decrease compared to 6,372,316.49 RMB in Q1 2020[17] - The net cash flow from investing activities was -51,764,957.47 RMB, primarily due to the purchase of financial products exceeding redemptions[17] - The net cash flow from financing activities increased to 445,933,421.47 RMB, attributed to funds raised from the company's IPO[17] - The cash inflow from financing activities included 447,342,486.13 RMB from investment absorption, indicating strong investor confidence[39] Research and Development - Research and development expenses as a percentage of operating revenue decreased by 6.03 percentage points to 7.06%[7] - Research and development expenses for Q1 2021 were ¥6,262,597.54, compared to ¥5,477,112.68 in Q1 2020, indicating an increase of 14.3%[29] - The company incurred R&D expenses of ¥5,386,318.21 in Q1 2021, slightly up from ¥5,037,011.03 in Q1 2020, indicating a focus on innovation[32] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30] - Future outlook includes potential market expansion strategies, although detailed projections were not provided in the conference call[47] - The company is exploring acquisition opportunities to enhance its market position, with a focus on strategic growth initiatives[47]